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Abstract
Background: The objectives of this study were to evaluate and model the probability of melanoma-specific death
and competing causes of death for patients with melanoma by competing risk analysis, and to build competing
risk nomograms to provide individualized and accurate predictive tools.
Methods: Melanoma data were obtained from the Surveillance Epidemiology and End Results program.
All patients diagnosed with primary non-metastatic melanoma during the years 2004–2007 were potentially eligible
for inclusion. The cumulative incidence function (CIF) was used to describe the probability of melanoma mortality
and competing risk mortality. We used Gray’s test to compare differences in CIF between groups. The proportional
subdistribution hazard approach by Fine and Gray was used to model CIF. We built competing risk nomograms
based on the models that we developed.
Results: The 5-year cumulative incidence of melanoma death was 7.1 %, and the cumulative incidence of
other causes of death was 7.4 %. We identified that variables associated with an elevated probability of
melanoma-specific mortality included older age, male sex, thick melanoma, ulcerated cancer, and positive
lymph nodes. The nomograms were well calibrated. C-indexes were 0.85 and 0.83 for nomograms predicting
the probability of melanoma mortality and competing risk mortality, which suggests good discriminative ability.
Conclusions: This large study cohort enabled us to build a reliable competing risk model and nomogram for
predicting melanoma prognosis. Model performance proved to be good. This individualized predictive
tool can be used in clinical practice to help treatment-related decision making.
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Background
In the United States, there were an estimated 76,690
new melanoma patients in 2013, causing approximately
9480 deaths [1]. At the time of diagnosis, a large propor-
tion of patients are diagnosed with localized disease [2].
According to data from the Surveillance, Epidemiology,
and End Results (SEER) program of the National Cancer
Institute, the 5-year overall survival rate for patients with
melanoma diagnosed between 2004 and 2012 was 81 %,
and for those with tumor size smaller than 1 mm, which
constitutes approximately 65 % of all newly diagnosed
melanomas, the outcomes are excellent, with a 5-year
survival rate of 89 % [3]. The majority of patients with
melanoma are cured by adequate surgical excision [4].
Given this situation, many patients may survive longer
and eventually die from non-cancer-related causes.
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Hence, competing causes of death should be taken into
account when evaluating the prognosis for patients with
melanoma. Moreover, the probabilities of melanoma-
specific mortality and competing risk mortality are
valuable when planning treatment and follow-up regi-
mens. However, these issues involving competing risk
analysis have not yet been well described for melanoma.
Therefore, the objectives of this study were to evaluate
and model the probability of melanoma-specific death
and competing causes of death for patients with mela-
noma by competing risk analysis, and to build compe-
ting risk nomograms to provide individualized and
accurate predictive tools using the SEER database, a
large population-based cohort.
Methods
Melanoma data were obtained from the National Cancer
Institute’s SEER program, Public Use Data, for the
period of 1973–2012 [3]. All patients with a diagnosis
of primary non-metastatic melanoma in the SEER-18
registries during the years 2004–2007 were potentially
eligible for inclusion in our study cohort. The SEER-18
registries cover approximately 28 % of the US popu-
lation and includes the registries of San Francisco
(SF) - Oakland, Connecticut, Detroit (Metropolitan),
Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah,
Atlanta (Metropolitan), San Jose-Monterey (SJM), Los
Angeles (LA), Alaska Natives, Rural Georgia, California
excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey,
and Greater Georgia. Institutional review board approval
and informed consent were not required in current study
because SEER Research Data is publicly available and all
patient data are de-identified. All authors have signed
authorization and received permission from SEER to
access and use the dataset.
The study cohort consisted of patients with the follo-
wing International Classification of Disease for Oncology,
Third Edition (ICD-O-3), histology codes: 8720–8723,
8728, 8730, 8740–8746, 8761, 8770–8774, and 8780; and
the ICD-O-3 site code C440–449. Only histologically
confirmed malignant melanoma cases were included.
Cancers diagnosed at autopsy or by death certificate only
were excluded. Additional patients were also excluded
for the following reasons: age, race, thickness, ulceration,
site, and N stage classified as unknown; tumor thickness
>9.8 mm; site coded as overlapping lesion of skin; cancer
diagnosed as metastatic tumors; and being younger than
20 years old. We further excluded those with SEER
surgical codes indicating that no cancer-directed surgery
had been performed, or it was unknown whether
cancer-directed surgery had been performed. Finally,
death cases with an SEER cause of death record indica-
ting that a death certificate was unavailable or was
available, but without information on the cause of death,
were excluded from the final cohort. The detailed data
selection process and criteria are shown in Fig. 1. After
data selection, our final study cohort included 40,043
cases diagnosed between 2004 and 2007, and followed
up through 2012.
The cumulative incidence of death is presented by
individual characteristics, as well as other clinical and
pathologic factors. Age was classified into three groups
(20–39 years, 40–64 years, and over 65 years). Tumor
thickness, node, and ulceration were divided according
to American Joint Committee on Cancer (AJCC) classi-
fication as follow: tumor thickness (≤1.00 mm, 1.01–
2.00 mm, 2.01–4.00 mm, and >4.00 mm); ulceration
(absent vs. present), and lymph node status (N0, N1, N2,
and N3). We also presented prognosis separately for
patients with stage I/II disease and stage III disease.
Histological subtype included superficial spreading mela-
noma, nodular melanoma, lentigo maligna melanoma,
malignant melanoma, not otherwise specified (NOS), and
other melanoma. Anatomic site was grouped as extre-
mities, trunk, face and ears, and scalp and neck.
Patients in the cohort were followed for vital status
until the earliest of the following dates: death; last con-
tact if before December 31, 2012; or December 31, 2012,
if the date of last contact was after 2012. Death from
melanoma and death from other causes were two event
types in the competing risk analysis. The information
regarding the cause of death came from death certifi-
cates. The cumulative incidence function was used to
describe the probability of melanoma mortality and com-
peting risk mortality. We used Gray’s test to compare
differences of CIF between groups [5]. The proportional
subdistribution hazard approach by Fine and Gray was
used to model CIF [6]. Unlike a cause-specific hazards
modeling approach, which requires modeling of both the
event of interest and competing risk events to calculate
CIF, in a subdistribution proportional hazards model, the
predicted risk at a specific time point is calculated based
on the cumulative subdistribution baseline hazard and the
estimates of the regression coefficients from the model.
Therefore, covariates in the fitted model can be incorpo-
rated into a nomogram easily [7, 8]. The exp (β) presents
the increase of the hazard of subdistribution owing to a
one unit crease of covariate x. A practical introduction on
competing risks analysis can also be found in Pintilie’s
book [9]. Variables used for modeling included age, tumor
thickness, sex, race, histological subtype, anatomic site,
ulceration, and lymph node status. Although over 40 % of
the patients were diagnosed as having malignant mela-
noma, NOS, we included it when developing models
because previous studies identified histological subtype as
an independent prognostic factor for patients with mela-
noma. Moreover, other published prognostic models for
melanoma using SEER data did not exclude histological
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subtype. To be consistent, in this study, histological sub-
type was included for modeling. When building predictive
nomograms, the study cohort was randomly divided into
training data (67 %) and validation data (33 %). A total of
26,829 cases as training data were used for building the
model, and 13,214 cases were used as a validation dataset
for evaluating model performance. The restricted cubic
splines with three knots at the 10, 50, and 90 % empirical
quantiles were fitted to model the variables of age at
diagnosis and tumor thickness, which were treated as
continuous variables in the model. The restricted cubic
splines approach is a method used in the modeling process
Fig. 1 Flow chart of data selection
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to relax linear assumptions for continuous predictors.
Function and more detailed explanation can be found in
Harrell’s book with regard to modeling strategy [10]. The
Bayesian information criterion was used for model selec-
tion. The proportional hazards assumption was examined
graphically with the plots of Schoenfeld-type residuals
against time failure for each variable in the model. Finally,
we built competing risk nomograms based on the models
that we developed.
Both discrimination and calibration were evaluated to
assess model performance. We used an index of prob-
ability of concordance between predicted probability and
response (c-index) to quantify discrimination. The c-index
can be defined as the proportion of all “evaluable ordered
patient pairs” for which the patients who died first had the
worse predicted outcome from the model [11]. A total
of 200 bootstraps were used to generate the confidence
interval for the c-index. To plot the calibration curve, the
validation cohort was divided into quintiles according to
predictions of probability of mortality. Subsequently, the
observed CIF was calculated for each quintile. We then
plotted the predictions of probability of mortality on the
x-axis and the observed CIF on the y-axis to form a
calibration curve. For a model that cali`brates well, the
dots in the calibration curve are located close to a 45°
diagonal line.
Statistical analyses were carried out with R version
3.1.0 software (Institute for Statistics and Mathematics,
Vienna, Austria; www.r-project.org) [12]. The R pack-
age rms [13] and cmprsk [14] were used for building
the model and nomogram. An R function provided by
Wolbers was used to calculate the c-index of the compe-
ting risk model [11]. All P values were calculated using
two-sided statistical testing.
Results
Characteristics of the patient cohort are listed in Table 1.
The cohort included 40,043 patients. In the whole
cohort, 14.8 % of patients were aged 20–39 years, 51.9 %
were aged 40–64 years, and 33.3 % were aged 65 years
or older. The majority of patients were male (55.7 %)
and white (98.8 %). Malignant melanoma, NOS (47.3 %)
was the most common histological subtype, followed by
superficial spreading melanoma (33.6 %), nodular mela-
noma (7.2 %), lentigo maligna melanoma (6.0 %), and
other melanomas (6.0 %). Approximately, 46.0 % of
melanomas occurred in the extremities, followed by
34.9, 12.0, and 7.0 % that were found in the trunk, face
and ears, or scalp and neck. A total of 68.1 % of patients
had tumors smaller than 1 mm. Ulceration was present
in 12.4 % of patients and 6.7 % had positive lymph node
involvement.
The median follow-up was 76 months (interquartile
range, 63–90). A total of 7216 patients died during the
follow-up period, of whom 3304 died from melanoma
and 3912 died owing to causes other than melanoma. Of
the 3912 patients who died of causes other than mela-
noma, the most common causes of competing mortality
were diseases of the heart (29.3 %), cerebrovascular
diseases (6.9 %), and lung and bronchus tumors (6.3 %).
Five-year estimates of the crude cumulative incidence of
death from melanoma and other causes by individual
characteristics, as well as clinical and pathologic factors,
are presented in Table 1. The 5-year cumulative inci-
dence of melanoma death was 7.1 % (95 % confidence
interval [CI], 6.8–7.3) and the cumulative incidence of
other causes of death was 7.4 % (95 % CI, 7.1–7.6). CIF
curves are plotted in Fig. 2. The 5-year cumulative pro-
bability of death from melanoma increased with increa-
sing age at diagnosis. The 5-year CIF for other causes of
death also increased with increasing age. The probability
of death from melanoma was significantly greater in
male than in female patients. Non-white patients were
more likely to die as a result of melanoma, and less likely
to die as a result of other causes than those of white
patients. Patients with nodular melanoma had a poor
prognosis, with a 25.6 % 5-year cumulative probability of
melanoma death and a 12.1 % 5-year probability for other
causes of death. Compared with melanoma that occurred
in the extremities and trunk, melanoma located in the
head and neck had a greater probability of death from
melanoma, and also a greater probability of death from
other causes. Both probability of melanoma-specific death
and other causes of death increased with increasing tumor
thickness. Patients with ulcerated disease had a poor prog-
nosis, with a 27.6 % 5-year cumulative probability of
melanoma death. Patients with positive node (stage III
disease) were more likely to die from melanoma than those
with negative node (stage I/II disease).
Coefficients and subdistribution hazard ratios (sdHR)
from the multivariable analysis are presented in Table 2.
Proportional subdistribution hazard assumption was held
for variables used for modeling. Age was strongly predic-
tive of melanoma-specific mortality. Increasing tumor
thickness was related to an increased probability of death
from melanoma. Race was a significant independent pre-
dictor for time of melanoma death, with a significant sdHR
of 1.82 (95 % CI, 1.42–2.32) for non-white patients,
compared with white patients. Patients with nodular
melanoma were more likely to die of melanoma than
those with superficial spreading melanoma, with a sdHR of
1.41 (95 % CI, 1.21–1.63). The anatomic site was a signi-
ficant independent predictor of melanoma death. In
addition, patients that presented with ulceration disease
were more likely to die of melanoma with sdHR of 1.98
(95 % CI, 1.72–2.22). Positive node was associated with an
increasing probability of melanoma death, with sdHR of
2.86 (95 % CI, 2.49–3.29), 3.41 (95 % CI 2.88–4.04), and
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5.69 (95 % CI 4.54–7.12) for N1, N2, and N3 disease,
respectively, compared with N0. The probability of death
from other causes was also modeled. Older patients, male,
white race, and negative lymph node involvement were
associated with a higher likelihood of death from non-
melanoma causes.
The nomograms based on models that we developed
are shown in Fig. 3. To use the nomogram, first, locate
Table 1 Five-year cumulative incidences of death among patients with melanoma
Cause-specific death Death from other causes
Characteristics N (%) Event 5-year (%) P 5-year (%) P
Total 40043 7216 7.1 (6.8 to 7.3) 7.4 (7.1 to 7.6)
Age (years) < 0.001 < 0.001
20–39 years 5940 (14.8) 262 3.3 (2.8 to 3.7) 0.4 (0.3 to 0.6)
40–64 years 20766 (51.9) 2069 5.7 (5.4 to 6.0) 2.3 (2.1 to 2.5)
65+ years 13337 (33.3) 4885 10.8 (10.3 to 11.3) 18.2 (17.5 to 18.9)
Sex < 0.001 < 0.001
Male 22295 (55.7) 4901 8.7 (8.3 to 9.1) 8.9 (8.5 to 9.3)
Female 17748 (44.3) 2315 5.0 (4.7 to 5.3) 5.4 (5.1 to 5.8)
Race < 0.001 0.006
White 39559 (98.8) 7075 6.9 (6.6 to 7.1) 7.4 (7.1 to 7.7)
Non-white 484 (1.2) 141 20.7 (17.2 to 24.4) 4.2 (2.7 to 6.3)
Melanoma subtype < 0.001 < 0.001
Superficial spreading melanoma 13444 (33.6) 1645 3.9 (3.6 to 4.2) 5.4 (5.0 to 5.8)
Nodular melanoma 2875 (7.2) 1233 25.6 (24.0 to 27.2) 12.1 (10.9 to 13.3)
Lentigo maligna melanoma 2383 (6.0) 547 3.4 (2.7 to 4.2) 14.5 (13.1 to 16.0)
Melanoma, NOS 18926 (47.3) 3131 6.2 (5.9 to 6.5) 6.9 (6.5 to 7.3)
Others 2415 (6.0) 660 12.8 (11.5 to 14.2) 9.2 (8.1 to 10.4)
Anatomic sites < 0.001 <0.001
Extremities 18427 (46.0) 2811 5.9 (5.6 to 6.3) 6.2 (5.9 to 6.6)
Trunk 13987 (34.9) 2250 6.9 (6.5 to 7.3) 5.9 (5.5 to 6.3)
Face and ears 4819 (12.0) 1331 8.0 (7.2 to 8.8) 13.8 (12.8 to 14.8)
Scalp and neck 2810 (7.0) 824 13.9 (12.6 to 15.2) 10.8 (9.6 to 11.9)
Thickness (mm) < 0.001 < 0.001
≤ 1.00 28017 (70.0) 3086 2.2 (2.0 to 2.4) 5.9 (5.7 to 6.3)
1.01–2.00 6279 (15.7) 1415 9.4 (8.7 to 10.2) 8.1 (7.5 to 8.8)
2.01–4.00 3464 (8.9) 1391 21.2 (19.9 to 22.6) 11.8 (10.8 to 12.9)
> 4.00 2283 (5.7) 1324 38.1 (36.1 to 40.1) 15.2 (13.7 to 16.7)
Ulceration < 0.001 < 0.001
Absent 35065 (87.6) 4916 4.1 (3.9 to 4.3) 6.6 (6.3 to 6.8)
Present 4978 (12.4) 2300 27.6 (26.4 to 28.9) 12.8 (11.9 to 13.8)
Lymph node status < 0.001 < 0.001
N0 37363 (93.3) 5889 4.8 (4.6 to 5.0) 7.4 (7.1 to 7.7)
N1 1543 (3.9) 650 31.0 (28.7 to 33.4) 6.0 (4.9 to 7.3)
N2 762 (1.9) 401 38.8 (35.5 to 42.3) 7.8 (6.0 to 9.9)
N3 375 (0.9) 276 63.8 (58.7 to 68.5) 6.2 (4.0 to 8.9)
Stage <0.001 < 0.001
I/II 37363 (93.3) 5889 4.8 (4.6 to 5.0) 7.4 (7.1 to 7.7)
III 2680 (6.7) 1327 37.8 (36.0–39.7) 6.5 (5.7–7.5)
Abbreviation: NOS malignant melanoma, not otherwise specified
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Fig. 2 Cumulative incidence estimates of death by patient characteristics (solid line, melanoma death; dotted line, non-melanoma death)
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the patient’s characteristic on the variable row, and
draw a vertical line straight up to the points’ row to
obtain a value of points for the variable. For example,
for a patient aged 50 years, if a vertical line is drawn
straight up to the “Point” row, we got around 20 points.
Then, repeat the process for each row and assign points
for each variable. Add up the total points and draw a
vertical line from the total points’ row to obtain the
probability of mortality. For example, if the sum of points
for each variables was “90”, the corresponding “5-year
probability of melanoma-specific death” would be a 5-year
probability of melanoma-specific death of 3.1 %. The
calibration plot is shown in Fig. 4. The calibration plot
indicates that the nomograms were well calibrated because
the predicted probability of mortality and the actual CIF
were in good agreement. C-indexes were 0.85 (95 % CI,
0.84–0.86) and 0.83 (95 % CI, 0.82–0.84) for nomograms
predicting the probability of melanoma mortality and
competing risk mortality, which suggests good model dis-
criminative ability.
Discussion
In this study, we estimated that the 5-year probability of
death for patients with non-metastatic melanoma diag-
nosed between 2004 and 2007 were 7.1 and 7.4 % for
cause-specific mortality and competing mortality, respec-
tively. Of the 7261 deaths in the study cohort, 3912 (54 %)
were owing to causes other than melanoma. We built
nomograms to serve as comprehensive and easily used
clinical tools that can predict the probability of melanoma-
specific mortality and mortality from other causes.
We found that older patients were more likely to die
of melanoma. These results are consistent with other
published studies. For example, Balch et al. used a co-
hort of 11,088 melanoma patients from the expanded
American Joint Committee on Cancer melanoma staging
database to evaluate survival among patients with mela-
noma. They found primary melanoma became more
advanced with increasing age. Moreover, older patients
with melanoma were more likely to have a disease with a
thicker tumor, higher mitotic rate, and were more like to
be ulcerated [15]. In addition, older patients were found to
be more likely to have age-related comorbid conditions
that prevent them from receiving the same standards of
care that are provided for younger patients [16].
Other characteristics associated with an elevated pro-
bability of melanoma mortality included: male, non-white,
thick tumor, present ulceration, nodular melanoma, head
and neck melanoma, and positive node status. Similar
results were also reported by Marashi-Pour et al. [17].
Table 2 Proportional subdistribution hazards models of probabilities of death
Cancer-specific mortality Other causes of mortality
Characteristics Coefficient sdHR (95 % CI) P Coefficient sdHR (95 % CI) P
Age 0.018 - < 0.001 0.06 - < 0.001
Age’ 0.001 - 0.85 0.032 - < 0.001
Thick 1.71 - < 0.001 - - -
Thick’ −3.659 - < 0.001 - - -
Female −0.234 0.79 (0.72 to 0.87) < 0.001 −0.359 0.70 (0.64 to 0.76) < 0.001
Non-white 0.601 1.82 (1.43 to 2.32) < 0.001 −0.583 0.56 (0.34 to 0.92) 0.02
Melanoma subtype - - - - - -
Nodular melanoma 0.341 1.41 (1.21 to 1.63) < 0.001 - - -
Lentigo maligna melanoma −0.114 0.89 (0.68 to 1.17) 0.41 - - -
Malignant melanoma, NOS 0.213 1.24 (1.10 to 1.40) < 0.001 - - -
Other melanomas 0.272 1.31 (1.10 to 1.57) < 0.001 - - -
Anatomic sites - - - - - -
Trunk 0.23 1.26 (1.13 to 1.40) < 0.001 - - -
Face and ears 0.277 1.32 (1.14 to 1.52) < 0.001 - - -
Scalp and neck 0.503 1.65 (1.41 to 1.94) < 0.001 - - -
Ulceration (present) 0.683 1.98 (1.77 to 2.22) < 0.001 - - -
Lymph node status - - - - - -
N1 1.051 2.86 (2.49 to 3.29) < 0.001 −0.201 0.82 (0.64 to 1.05) 0.11
N2 1.228 3.41 (2.88 to 4.04) < 0.001 −0.16 0.85 (0.62 to 1.14) 0.29
N3 1.739 5.69 (4.54 to 7.12) < 0.001 −0.58 0.56 (0.33 to 0.95) 0.03
Abbreviations: sdHR subdistribution hazard ratio
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They studied 52,330 invasive melanomas in New South
Wales using a competing risk method, and found that
older patients, male patients, patients with thick tumors,
non-localized disease, nodular melanoma, and patients
with head neck melanoma showed a high risk of mela-
noma mortality [17].
The prognostic nomogram is a model-based prediction
tool that incorporates clinical and pathologic risk factors
Fig. 3 Nomogram for predicting 5- and 8-year probabilities of mortality in patients with melanoma. Abbreviations: Sex: F, female; M, male; Race:
W, white; NonW, non-white; Histology: Su, superficial spreading melanoma; No, nodular melanoma; L, lentigo maligna melanoma; NOS, malignant
melanoma, not otherwise specified; O, other melanomas; Site: E, extremities; T, trunk; F, face and ears; S, scalp and neck; MSD, melanoma-specific
death; OCD, other causes of death. Instructions: Locate the patient’s characteristic on the variable row, and draw a vertical line straight up to the
points’ row to obtain a value of points for the variable. Repeat this process, and assign points for each variable. Add up the total points and draw
a vertical line from the total points’ row to obtain the probability of mortality ((a), melanoma-specific death; (b), other causes of death)
Shen et al. BMC Cancer  (2016) 16:413 Page 8 of 11
known to have an impact on outcome [18, 19]. Although
the TNM staging system has significant predictive
capability for the prognosis of patients with melanoma,
some important risk factors, such as age, are not included.
As mentioned above, age is an independent predictive
factor of melanoma mortality. Without considering age,
regarding all patients within the same TNM category as a
homogeneous group may lead to a bias in estimating the
prognosis. The nomograms described here not only
include tumor thickness, node status, and ulceration that
are used for AJCC classification, but also incorporate
demographic characteristics. Moreover, different from a
scoring system, a nomogram provides a quantified prog-
nosis for individual patients, so it is more acute and
informative.
Estimating prognosis based on individual risk profiles
is important for patient counseling and decision making.
For example, in clinical practice, the prediction of prog-
nosis and risk classification can help clinicians to devise
treatments and make a follow-up plan. In addition, it
can be used in clinical studies to identify and select the
appropriate patient population based on predicted prog-
nosis, and it can help to create subgroups for comparing
the effectiveness of a treatment within each subgroup. In
addition, predicted prognosis can also be incorporated
into a multivariate model as an adjusting factor when
evaluating different treatment strategies [20].
Melanoma is a cancer with a good prognosis, having
a 10-year metastasis-free survival rate of 91.8–99.5 %
[21–23]. In our study cohort, over 50 % of the deaths
were owing to factors other than the primary cancer.
Such competing risks of death should be taken into
account when evaluating prognosis. Recently, compe-
ting risk nomograms have been developed for sarcoma
[24], breast cancer [25], prostate cancer [26], renal cell
carcinoma [27], thyroid cancer [7], and head and neck
cancer [8]. To our knowledge, this is the first effort to
construct a competing risk nomogram for melanoma
using a population-based cohort. The nomograms pre-
sented here have good discrimination ability with a high
c-index of 0.85 for predicting melanoma-specific death
and 0.83 for death by other causes. The calibration plot
also demonstrates that the predicted probability from
nomograms corresponds well with the observed CIF.
One of the greatest strengths of this study is the large
cohort size and the high quality of the SEER database. The
SEER dataset contains data on cancer incidence and
survival collected from population-based cancer registries.
The results from a population-based study are more likely
to be generalizable than those from single-institute
studies, which are potentially subject to selection bias [28].
Information about the cause of death in SEER data can
allow us to estimate the probability of cancer-specific death
based on competing risk analysis [7, 8]. Furthermore, our
Fig. 4 Calibration plot. The X-axis designates the mean predicted probability of mortality based on the model. The Y-axis indicates the observed
cumulative incidence of death. The solid line represents equality between the predicted and observed values
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study cohort has more than 40,043 patients with micro-
scopically confirmed melanoma, including information on
thickness and ulceration. This sample size is sufficiently
large to allow a predictive model to be built accurately.
In interpreting the results of this study, it is important
to acknowledge that some variables that may be associated
with prognosis are not included in the models, such as
comorbidity. Although comorbidity is not included in the
predictive model, we believe that age can be regarded as a
proxy to offset the impact caused by the lack of comor-
bidity. Other limitations include the lack of a centralized
review of diagnostic specimens and over 50 % of patients
being classified as having other or not otherwise specified
melanoma. In addition, the accuracy of the data on cause
of death is an issue of concern. A study evaluating the
validity of cause-of-death certification for melanoma
concluded that 93 % of deaths attributable to melanoma
were actually certified as being owing to melanoma [29].
Hence, we think that the bias due to mis-recording the
cause of death might have been small in the current study.
Other limitations involving testing and explanation of
the model and nomogram should also be mentioned
here. First, the large sample size may lead to very small
p values in statistical tests. Second, summing the pre-
dicted probability of melanoma mortality and non-
melanoma mortality from nomograms may exceed one for
the high-risk group [7]. Third, including a longer follow-up,
as well as novel predictors, such as mitotic rate, serum
lactate dehydrogenase, and comorbidity, may improve
the nomogram and thereby increase model accuracy.
In addition, external validation based on other populations
to provide a more accurate evaluation of model perfor-
mance is still needed. Finally, although our models have
been demonstrated to perform well and allow us to
predict the probability of death from melanoma and other
causes, the predicted value does not represent the
absolute accurate probability of melanoma prognosis
because it is impossible to explain all of the risk factors for
melanoma-specific mortality or non-cancer mortality in
these models.
Conclusion
In conclusion, in this study, we used a large population-
based cohort to estimate the cumulative incidence of
melanoma-specific mortality and other causes of death in
patients diagnosed with melanoma. The large study cohort
enabled us to build a reliable competing risk model and
nomogram. Model performance was found to be good.
This individualized predictive tool can be used in clinical
practice to help in treatment-related decision making.
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